Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial

被引：0
|
作者：
Bingham, Clifton O., III [1 ]
Weinblatt, Michael [2 ]
Mendelsohn, Alan [3 ]
Kim, Lilianne [3 ]
Mack, Michael [3 ]
Lu, Jiandong [3 ]
Baker, Daniel [3 ]
Westhovens, Rene [4 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Univ Hosp KU Leuven, Louvain, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1301
引用
收藏
页码：S558 / S558
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study
    Yang, Yue
    Li, Jingyang
    Liu, Ju
    Liu, Lin
    Wang, Yongfu
    Hu, Jiankang
    Li, Zhijun
    Gu, Jieruo
    Zhang, Xiao
    Xiao, Zhengyu
    Zheng, Junjie
    Liu, Lin
    Li, Zhanguo
    Wei, James Cheng-Chung
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
  • [42] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    Smolen, Josef S.
    Pangan, Aileen L.
    Emery, Paul
    Rigby, William
    Tanaka, Yoshiya
    Vargas, Juan Ignacio
    Zhang, Ying
    Damjanov, Nemanja
    Friedman, Alan
    Othman, Ahmed A.
    Camp, Heidi S.
    Cohen, Stanley
    LANCET, 2019, 393 (10188): : 2303 - 2311
  • [43] Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
    Hara, Masako
    Ishiguro, Naoki
    Katayama, Kou
    Kondo, Masakazu
    Sumida, Takayuki
    Mimori, Tsuneyo
    Soen, Satoshi
    Nagai, Kota
    Yamaguchi, Tomonobu
    Yamamoto, Kazuhiko
    MODERN RHEUMATOLOGY, 2014, 24 (03) : 410 - 418
  • [44] Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo controlled multicenter trial.
    Kavanaugh, AF
    Cush, JJ
    StClair, EW
    McCune, WJ
    Braakman, TAJ
    Nichols, LA
    Linsky, PE
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 575 - 575
  • [45] FIVE-YEAR SAFETY AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PRIOR TREATMENT WITH METHOTREXATE: FINAL STUDY RESULTS OF THE PHASE 3, RANDOMIZED PLACEBO-CONTROLLED GO-FORWARD TRIAL
    Keystone, E.
    Genovese, M. C.
    Hall, S.
    Miranda, P. C.
    Bae, S. -C.
    Han, C.
    Gathany, T.
    Zhou, Y.
    Xu, S.
    Hsia, E. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 867 - 868
  • [46] Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
    Weinblatt, Michael
    Bingham, Clifton O., III
    Mendelsohn, Alan
    Noonan, Lenore
    Sheng, Shihong
    Kim, Lilianne
    Hung, Kim
    Lu, Jiandong
    Baker, Daniel
    Westhovens, Rene
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S353 - S354
  • [47] INTRAVENOUS GOLIMUMAB INHIBITS RADIOGRAPHIC PROGRESSION AND MAINTAINS CLINICAL EFFICACY AND SAFETY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: 1-YEAR RESULTS OF A PHASE 3 TRIAL
    Weinblatt, M.
    Bingham, C. O., III
    Mendelsohn, A.
    Noonan, L.
    Sheng, S.
    Kim, L.
    Hung, K.
    Lu, J.
    Baker, D.
    Westhovens, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 238 - 238
  • [48] Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study
    David L. Boyle
    Samuel E. DePrimo
    Cesar Calderon
    Dion Chen
    Paul J. Dunford
    William Barchuk
    Gary S. Firestein
    Robin L. Thurmond
    Inflammation Research, 2019, 68 : 261 - 274
  • [49] Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study
    Boyle, David L.
    DePrimo, Samuel E.
    Calderon, Cesar
    Chen, Dion
    Dunford, Paul J.
    Barchuk, William
    Firestein, Gary S.
    Thurmond, Robin L.
    INFLAMMATION RESEARCH, 2019, 68 (04) : 261 - 274
  • [50] Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
    Xiaoying Zhang
    Miao Miao
    Ruijun Zhang
    Xu Liu
    Xiaozhen Zhao
    Miao Shao
    Tian Liu
    Yuebo Jin
    Jiali Chen
    Huixin Liu
    Xia Zhang
    Yun Li
    Yunshan Zhou
    Yue Yang
    Ru Li
    Haihong Yao
    Yanying Liu
    Chun Li
    Yuhui Li
    Limin Ren
    Yin Su
    Xiaolin Sun
    Jing He
    Zhanguo Li
    Signal Transduction and Targeted Therapy, 7
12345